The discovery of mutations in the tyrosine kinase (TK) domain of the EGFR in lung cancers has generated enormous interest since they appear to be associated with sensitivity to EGFR-tyrosine kinase inhibitors (TKIs). These mutations appear to occur predominantly in highly select patient populations: East Asian ethnicity, female gender, never-smoker status and adenocarcinoma subtype. While the mutational status of EGFR appears to be of considerable importance in determining response to EGFR-TKIs in lung cancer, it is not the sole factor. Accurate prediction of therapeutic response to EGFR-TKIs is likely to require a complete understanding of the erbB gene family members and their role in cancer pathogenesis and progression. Further molecular-based studies are required to analyse the biological functions of different EGFR-TK mutations and to assess their effect on sensitivity to EGFR-TKIs. Epidemiological studies may identify other possible factor(s) associated with the incidence of EGFR-TK mutations or with response to EGFR-TKIs.
|Original language||English (US)|
|Number of pages||5|
|State||Published - May 1 2005|
ASJC Scopus subject areas
- Drug Discovery
- Pharmacology (medical)